BioGraphic Signs Midway For AI.Implant

AI middleware firm BioGraphic Technologies has announced that Midway has signed an agreement with BGT to use AI.implant as its standard and preferred AI engine. AI.implant will immediately roll out into projects in Midway's Chicago, Seattle and Austin studios, including titles such as next-gen John Woo action game Stranglehold, with other projects to follow shortly. "We have been working with BGT since 2002 and have seen a tremendous evolution in the AI.implant engine," said Paul LeFevre, Chief Technical Officer, Midway Games. "Great AI is becoming of one of key differentiators in our next-gen titles and we felt that the strengths of BGT and AI.implant make it a great platform to standardize on. We look forward to many great titles together." "Midway was our first game customer and so it is only fitting that they are the first company to standardize on us," said Dr. Paul Kruszewski, President and founder of BioGraphic Technologies, Inc. "Midway's standardization is a real vote of confidence in the maturity of the AI.implant technology and the strength of BGT as a business partner."